Tempus AI (NASDAQ:TEM) Director Sells $21,981.70 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $59.41, for a total value of $21,981.70. Following the sale, the director directly owned 26,051 shares of the company’s stock, valued at $1,547,689.91. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tempus AI Stock Performance

TEM stock traded down $2.42 during midday trading on Wednesday, hitting $53.55. The company’s stock had a trading volume of 9,600,266 shares, compared to its average volume of 5,760,559. The stock has a market cap of $9.53 billion, a price-to-earnings ratio of -45.00 and a beta of 5.22. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The stock’s 50-day moving average price is $67.79 and its 200 day moving average price is $74.07. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business’s revenue for the quarter was up 84.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.46) EPS. On average, equities analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TEM shares. Morgan Stanley boosted their target price on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Needham & Company LLC upped their price objective on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Canaccord Genuity Group reduced their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. HC Wainwright lowered their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Piper Sandler dropped their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $87.20.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its position in shares of Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares in the last quarter. Global Retirement Partners LLC raised its stake in shares of Tempus AI by 29.5% during the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after purchasing an additional 167 shares during the period. US Bancorp DE raised its stake in shares of Tempus AI by 6.6% during the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after purchasing an additional 176 shares during the period. Legacy Bridge LLC lifted its holdings in Tempus AI by 1.6% during the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after purchasing an additional 193 shares in the last quarter. Finally, Truist Financial Corp boosted its stake in Tempus AI by 5.8% in the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares during the period. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.